Diagnostic challenges of high-grade myeloid malignancies with partial plasmacytoid dendritic cell differentiation: report of two cases with literature review

Genitourinary Cancer

Spontaneous regression of metastatic clear cell renal cell carcinoma: A report of a rare case and a review of the literature

Urol Case Rep

Mullasseril A, Lam AB, Mitta A, Morton D, McIntosh A, Patel S, Thai T, Annan A, Ayanambakkam A

doi: 10.1016/j.eucr.2024.102868

Lymphoma

Efficacy of intravenous high-dose methotrexate in preventing relapse to the central nervous system in R-CHOP(-like)-treated, high-risk, diffuse large B-cell lymphoma patients and its effect on mortality: a systematic review and meta-analysis

Haematologica

Tolley ER, Lewinter C, Pedersen LM, Nielsen TH

doi: 10.3324/haematol.2023.284281

Genitourinary Cancer

Analysis of three primary prostatic sarcoma cases and literature review

Prostate

Wei Y, Wang H, Xie D, Lu J, Liang X, He W, Yang P, Wang J

doi: 10.1002/pros.24758

Further Publications

Second primary malignancies after CAR T-cell therapy: A systematic review and meta-analysis of 5,517 lymphoma and myeloma patients

Clin Cancer Res

Tix T, Alhomoud M, Shouval R, Cliff ERS, Perales MA, Cordas Dos Santos DM, Rejeski K

doi: 10.1158/1078-0432.CCR-24-1798

Lymphoma

CNS Relapse in High-Grade B-cell Lymphoma with MYC and BCL2 Rearrangements and Dark-Zone Signature-Expressing DLBCL

Blood

Alduaij W, Jiang A, Villa D, Collinge BJ, Ben-Neriah S, Boyle M, Meissner B, Hilton LK, Farinha P, Slack GW, Craig JW, Gerrie AS, Freeman CL, Mungall AJ, Steidl C, Sehn LH, Scott DW, Savage KJ

doi: 10.1182/blood.2024025725

Myeloproliferative Neoplasms (MPNs)

Real world predictors of response and 24-month survival in high-grade TP53-mutated myeloid neoplasms

Blood Cancer J

Kaur A, Rojek AE, Symes E, Nawas MT, Patel AA, Patel JL, Sojitra P, Aqil B, Sukhanova M, McNerney ME, Wu LP, Akmatbekov A, Segal J, Tjota MY, Gurbuxani S, Cheng JX, Yeon SY, Ravisankar HV, Fitzpatrick C, Lager A, Drazer MW, Saygin C, Wanjari P, Katsonis P, Lichtarge O, Churpek JE, Ghosh SB, Patel AB, Menon MP, Arber DA, Wang P, Venkataraman G

doi: 10.1038/s41408-024-01077-9

Further Publications

Development of a conceptual framework for an electronic patient-reported outcome (ePRO) system measuring symptoms and impacts of CAR T-cell therapies in patients with haematological malignancies

Lancet Oncol

Khatsuria F, McMullan C, Aiyegbusi OL, Shaw KL, Iqbal R, Kinsella F, Wilson K, Pyatt L, Lewis M, Wheldon SMR, Burns D, Chakraverty R, Calvert M, Hughes SE

doi: 10.1016/S1470-2045(24)00256-0

Further Publications

Second Primary Malignancies After Commercial CAR T Cell Therapy: Analysis of FDA Adverse Events Reporting System (FAERS)

Blood

Elsallab M, Ellithi M, Lunning MA, D'Angelo C, Ma J, Perales MA, Frigault MJ, Maus MV

doi: 10.1182/blood.2024024166

Sarcoma

The challenge of running trials in advanced angiosarcoma: A systematic review of the literature from EORTC/STBSG to guide the development of angiosarcoma-specific trials

Eur J Cancer

Dufresne A, Lindner LH, Striefler J, Kasper B, Van Houdt W, Litiere S, Marreaud S, Blay JY, D'Ambrosio L, Stacchiotti S

doi: 10.1016/j.ejca.2024.114188

Related content

Spontaneous regression of metastatic clear cell renal cell carcinoma: A report of a rare case and a review of the literature

Efficacy of intravenous high-dose methotrexate in preventing relapse to the central nervous system in R-CHOP(-like)-treated, high-risk, diffuse large B-cell lymphoma patients and its effect on mortality: a systematic review and meta-analysis

Analysis of three primary prostatic sarcoma cases and literature review

Second primary malignancies after CAR T-cell therapy: A systematic review and meta-analysis of 5,517 lymphoma and myeloma patients

CNS Relapse in High-Grade B-cell Lymphoma with MYC and BCL2 Rearrangements and Dark-Zone Signature-Expressing DLBCL

Real world predictors of response and 24-month survival in high-grade TP53-mutated myeloid neoplasms

Development of a conceptual framework for an electronic patient-reported outcome (ePRO) system measuring symptoms and impacts of CAR T-cell therapies in patients with haematological malignancies

Second Primary Malignancies After Commercial CAR T Cell Therapy: Analysis of FDA Adverse Events Reporting System (FAERS)

The challenge of running trials in advanced angiosarcoma: A systematic review of the literature from EORTC/STBSG to guide the development of angiosarcoma-specific trials